Logo

AstraZeneca Reports Results of Imfinzi in P-III (AEGEAN) Trial for the Treatment of Non-Small Cell Lung Cancer

Share this
AstraZeneca Reports Results of Imfinzi in P-III (AEGEAN) Trial for the Treatment of Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi in P-III (AEGEAN) Trial for the Treatment of Non-Small Cell Lung Cancer

Shots:

  • The P-III (AEGEAN) trial evaluates the safety & tolerability of Imfinzi + neoadjucant CT vs CT alone in patients with NSCLC
  • The results from the combination therapy demonstrated a statistically significant improvement in pCR & MPR, consistent safety & tolerability, without a decrease in the number of patients to be able to undergo successful surgery vs CT alone
  • The company is evaluating Imfinzi in other ongoing trials for the treatment of early stages of lung cancer incl. NSCLC (ADJUVANT BR.31), unresectable NSCLC (PACIFIC-2/4/5/8/9) & limited-stage SCLC (ADRIATIC). Imfinzi has also been approved in the US, Japan, China, the EU & other countries for the treatment of unresectable stage III NSCLC based P-III (PACIFIC) trial & extensive-stage SCLC based on the P-III (CASPIAN) trial

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions